BPC-157 — Research Product Overview

**Disclaimer:** This product overview is provided strictly for in-vitro and preclinical research use. [BPC-157](/catalog/bpc-157) is not approved by the FDA for human use, is not a drug, food, or cosmetic, and nothing in this document constitutes medical advice or a recommendation for human administration. Materials are sold to qualified research professionals for laboratory investigation only.

Overview

Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a partial sequence of a cytoprotective protein originally identified in human gastric juice. Since its initial characterization by the Sikiric laboratory at the University of Zagreb in the early 1990s, BPC-157 has accumulated one of the most extensive preclinical literatures of any cytoprotective peptide, with reproducible reports of accelerated repair across gastrointestinal, tendon, ligament, muscle, and vascular injury models. Its unusual stability in acidic conditions and across enzymatic challenges distinguishes it from the majority of bioactive peptides.

For a deeper treatment of the mechanistic literature — including FAK-paxillin signaling, nitric oxide modulation, and VEGF-mediated angiogenesis — see our companion article on BPC-157 mechanisms of accelerated tissue repair. Researchers cataloging the broader regenerative-peptide landscape may also find the peptides longevity research 2026 overview useful for situating BPC-157 alongside contemporary tool compounds.

Sequence and Structural Notes

• Amino acid sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
• Single-letter code: GEPPPGKPADDAGLV
• Molecular formula: C62H98N16O22
• Molecular weight: 1419.53 Da (monoisotopic 1418.71)
• Length: 15 amino acids (pentadecapeptide)
• Net charge at pH 7: approximately -2
• N-terminus: free amine (acetate counter-ion in lyophilized form)
• C-terminus: free acid

The peptide contains three consecutive proline residues (positions 3–5), which impart conformational rigidity and substantial resistance to proteolytic degradation. This structural feature is widely cited as the basis for BPC-157's reported stability in gastric acid, intestinal homogenates, and human plasma in vitro.

Mechanism of Action (Summary)

No high-affinity receptor for BPC-157 has been identified. Reported mechanisms include:

1. Nitric oxide system modulation — bidirectional effects on eNOS, nNOS, and iNOS, normalizing NO tone where it is dysregulated.
2. FAK-paxillin pathway activation — promotes phosphorylation of FAK Tyr397 and paxillin Tyr118 in tendon fibroblasts, driving migration and survival.
3. VEGF-mediated angiogenesis — increased VEGF expression and capillary density in wound beds.
4. Growth hormone receptor [upregulation](/research/glossary#upregulation) — increased GHR expression in tendon fibroblasts, sensitizing tissue to endogenous GH.
5. Dopaminergic and serotonergic modulation — relevant to GI cytoprotection and gut-brain signaling.

Preclinical Research Summary

The BPC-157 literature spans hundreds of rodent studies. Representative findings include accelerated Achilles tendon healing post-transection (Staresinic et al. 2003), reduced gastric ulceration from ethanol/NSAID/restraint stress, attenuation of TNBS- and DSS-induced colitis, improved muscle regeneration after crush injury, and protection against arterial and venous thrombosis. Most studies use intraperitoneal or intragastric administration in rats at doses of 10 ng/kg to 10 µg/kg. A Phase II trial in inflammatory bowel disease (APCER-GI-001) has been registered but no completed Phase I, II, or III human trial data are available as of early 2026.

Comparator Peptides and Molecules

BPC-157 is most often discussed alongside thymosin beta-4 (TB-500), the other dominant regenerative research peptide of the past two decades. The two molecules approach tissue repair from different mechanistic angles: BPC-157 is a 15-amino-acid pentadecapeptide acting through FAK-paxillin migration signaling, eNOS/nNOS modulation of vascular tone, and growth-hormone-receptor sensitization, while TB-500 is a 43-amino-acid intracellularly abundant actin-sequestering peptide whose extracellular activities are propagated through ILK/Akt signaling and VEGF/MMP induction. The pentadecapeptide is unusually stable in gastric and intestinal environments, while the longer thymosin requires parenteral administration in nearly every published model. A side-by-side treatment is available in the BPC-157 vs TB-500 comparison article.

GHK-Cu, a copper-loaded tripeptide, occupies a third corner of the regenerative tripod by emphasizing extracellular-matrix remodeling, antioxidant defense, and copper-dependent enzymatic reactions rather than the migratory and angiogenic emphasis of BPC-157 — see GHK-Cu vs BPC-157 in wound healing for a focused contrast. Researchers building cocktails should also consider the BPC-157 / TB-500 blend overview, which provides additive coverage of the FAK-paxillin and ILK/Akt repair branches without claiming receptor-level synergy. For broader signaling context, BPC-157 intersects the nitric-oxide-peptides axis and the growth-hormone axis, which provides a useful framing for distinguishing its receptor-independent mechanism from peptides with defined GHRH or GHS-R targets.

Deeper Preclinical Breakdown

Staresinic et al. 2003 (PMID 12749078) used a transected rat Achilles tendon model (Sprague-Dawley, both sexes) to evaluate intraperitoneal BPC-157 at 10 µg/kg and 10 ng/kg. Tendons were transected with a scalpel through the mid-substance, repaired with one figure-of-eight suture, and animals received daily IP injections through day 14 post-op. Biomechanical testing showed significantly higher load-to-failure in BPC-treated tendons at both doses, and histology demonstrated more organized collagen orientation. The dose flatness (10 ng/kg producing similar repair to 10 µg/kg) is one of the more reproducible features of the BPC-157 literature; the limitation is that this same flatness has obstructed the construction of a dose-response curve usable for translation.

Chang et al. 2011 (PMID 21172366) provided the canonical mechanistic study, using primary tendon-derived fibroblasts from rat Achilles tendons. Cells were treated with BPC-157 across a 1 nM to 100 µM range, and immunoblotting showed concentration-dependent phosphorylation of FAK at Tyr397 and paxillin at Tyr118 within 30 minutes of exposure, accompanied by enhanced migration in a Boyden chamber assay and accelerated cytoskeletal reorganization. The study has been the backbone of subsequent mechanistic work but did not identify the upstream receptor that connects extracellular BPC-157 to FAK activation, which remains the central unsolved problem in the literature.

Sikiric et al. 2018 (PMID 29886805) provides a comprehensive review consolidating gastrointestinal, tendon, ligament, muscle, brain, and cardiovascular findings across two decades of work, and is the most-cited single source for newcomers to the field. Its limitations are common to single-laboratory dominance: most cited primary papers originate from the Zagreb group, independent replication outside that group is uneven, and Phase II/III clinical trial data remain absent.

Formulation Considerations

BPC-157 is supplied as a lyophilized powder, typically 5 mg or 10 mg per vial, produced by solid-phase peptide synthesis followed by reverse-phase HPLC purification. The proline-rich core resists most proteases and confers strong shelf stability, but the lyophilizate is hygroscopic and should remain desiccated. Bacteriostatic water for injection (BWFI, 0.9% benzyl alcohol) is the standard reconstitution diluent for research applications and provides multi-week stability when the reconstituted vial is stored at 2–8 °C. Sterile water and 0.05% acetic acid are alternatives, with the latter sometimes used to improve very-short-term solubility at higher concentrations.

Common impurities visible on a high-quality COA include des-amido variants from Asp/Asn residues, truncated 14-mer fragments from incomplete coupling at the proline-rich region, and acetate counter-ion residue (typically <15% w/w). Light exposure causes only minor degradation, but room-temperature storage of reconstituted material accelerates des-amidation; aliquoting and freezing at -20 °C or -80 °C is preferred for long-term use. For a deeper handling treatment see the peptide storage and reconstitution guide and peptide solubility guide.

Research-Context Dosing Ranges

Published preclinical studies have used a remarkably wide concentration range. In-vitro fibroblast assays have employed 1 nM to 100 µM (Chang et al. 2011). Rodent tendon-repair and gastric-ulcer models have most commonly used 10 ng/kg or 10 µg/kg intraperitoneally, with intragastric work using 10 µg/kg in drinking water. Colitis models have used similar ranges. The dose-response relationship is unusually flat across this five-log span, complicating translation. Researchers designing new studies should benchmark against the 10 µg/kg IP rodent reference dose unless they have specific reason to deviate. No dosing recommendation is implied for human use.

Common Research Applications

• In-vitro tendon, ligament, and skeletal-muscle fibroblast assays (migration, proliferation, collagen output)
• Rodent transection and crush-injury repair models
• Gastrointestinal lesion and colitis models (ethanol, indomethacin, TNBS, DSS)
• Endothelial tube-formation and chick chorioallantoic membrane (CAM) angiogenesis assays
• Comparative regenerative-peptide studies, especially against TB-500 — see BPC-157 vs TB-500

Handling, Reconstitution, and Storage

• Form supplied: white-to-off-white lyophilized powder, typically 5 mg or 10 mg per vial
• Reconstitution: bacteriostatic water for injection (BWFI) or sterile water; some protocols use 0.05% acetic acid for improved short-term solubility
• Working concentration: 0.5–2 mg/mL is typical for in-vitro work
• Lyophilized stability: ≥24 months at -20 °C protected from light and moisture
• Reconstituted stability: up to 14 days at 2–8 °C; for longer-term storage, aliquot and freeze at -20 °C or -80 °C; avoid repeated freeze-thaw cycles
• Avoid: vigorous vortexing, which can shear the peptide; reconstitute by gentle swirling

For broader handling guidance see our peptide reconstitution guide and peptide storage stability overview.

Lab Specifications

• HPLC purity target: ≥98.0% by RP-HPLC at 220 nm
• Identity confirmation: ESI-MS or MALDI-TOF; observed mass within ±1 Da of theoretical 1419.53
• Acetate content: typically <15% w/w (TFA-free preparations available on request)
• Endotoxin: <1 EU/mg by LAL where specified for cell-culture grade
• Residual solvents: within ICH Q3C limits
• Water content: <8% by Karl Fischer

A certificate of analysis (COA) accompanies every lot. For interpretive guidance see how to read a peptide COA.

Cross-References

Related Viking Labs research:

• BPC-157 mechanisms of accelerated tissue repair
• BPC-157 vs TB-500 comparison
• GHK-Cu vs BPC-157 wound healing
• Product overview: TB-500
• Product overview: BPC/TB blend
• Research peptide buying guide
• WADA prohibited list 2026

Summary

BPC-157 remains one of the most extensively studied cytoprotective peptides in the preclinical literature. Its proline-rich core confers the unusual stability that has driven research interest, and its mechanistic profile — NO modulation, FAK-paxillin activation, and pro-angiogenic effects — accounts for the reproducible regenerative phenotypes observed across organ systems. Researchers should consult the primary literature when designing experiments and treat all human translation as speculative pending controlled clinical data.

*This document is provided for research and educational purposes only. Viking Labs does not sell products intended for human consumption.*